Shares of Ascendis Pharma (ASND) are down $5.82, or 4%, to $155.33 in morning trading in New York. The move lower began near the open and may ...

RBC Capital initiated coverage of Ascendis Pharma (ASND) with an Outperform rating and $205 price target. The stock has outperformed the ...

ASND thrives amid market volatility, with Yorvipath's strong potential & strategic focus on rare diseases. Click here to find ...

We recently published a list of 10 Best Growth Stocks to Buy According to Billionaires. In this article, we are going to take ...

Detailed price information for Ascendis Pharma ADR (ASND-Q) from The Globe and Mail including charting and trades.